GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (FRA:TKDA) » Definitions » Cyclically Adjusted PS Ratio

Takeda Pharmaceutical Co (FRA:TKDA) Cyclically Adjusted PS Ratio : 1.62 (As of Jun. 10, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Takeda Pharmaceutical Co's current share price is €12.20. Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €7.54. Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio for today is 1.62.

The historical rank and industry rank for Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:TKDA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.34   Med: 1.84   Max: 3.13
Current: 1.73

During the past years, Takeda Pharmaceutical Co's highest Cyclically Adjusted PS Ratio was 3.13. The lowest was 1.34. And the median was 1.84.

FRA:TKDA's Cyclically Adjusted PS Ratio is ranked better than
55.85% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs FRA:TKDA: 1.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted revenue per share data for the three months ended in Mar. 2024 was €2.011. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.54 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 1.82 1.56 1.85 1.71

Takeda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 1.90 1.93 1.67 1.71

Competitive Comparison of Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=12.20/7.54
=1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Takeda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.011/107.2000*107.2000
=2.011

Current CPI (Mar. 2024) = 107.2000.

Takeda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.880 98.000 2.056
201409 2.019 98.500 2.197
201412 2.108 97.900 2.308
201503 2.137 97.900 2.340
201506 2.034 98.400 2.216
201509 2.148 98.500 2.338
201512 2.337 98.100 2.554
201603 2.101 97.900 2.301
201606 2.335 98.100 2.552
201609 2.328 98.000 2.547
201612 2.422 98.400 2.639
201703 2.186 98.100 2.389
201706 2.290 98.500 2.492
201709 2.088 98.800 2.266
201712 2.322 99.400 2.504
201803 1.943 99.200 2.100
201806 2.224 99.200 2.403
201809 2.091 99.900 2.244
201812 2.481 99.700 2.668
201903 1.837 99.700 1.975
201906 2.227 99.800 2.392
201909 2.192 100.100 2.347
201912 2.275 100.500 2.427
202003 2.062 100.300 2.204
202006 2.113 99.900 2.267
202009 2.016 99.900 2.163
202012 2.103 99.300 2.270
202103 1.890 99.900 2.028
202106 2.303 99.500 2.481
202109 2.062 100.100 2.208
202112 2.225 100.100 2.383
202203 2.122 101.100 2.250
202206 2.209 101.800 2.326
202209 2.259 103.100 2.349
202212 2.443 104.100 2.516
202303 2.109 104.400 2.166
202306 2.208 105.200 2.250
202309 2.112 106.200 2.132
202312 2.226 106.800 2.234
202403 2.011 107.200 2.011

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Takeda Pharmaceutical Co  (FRA:TKDA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (FRA:TKDA) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (FRA:TKDA) Headlines

No Headlines